Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Biohaven’s stock fell in premarket trading on Monday after it announced a Phase 3 trial failure of its myostatin inhibitor in spinal muscular atrophy and obesity. The RESILIENT study did not ...